2011

September 20, 2011	Apogenix Successfully Completes Patient Recruitment for Glioblastoma Phase II Trial with APG101
January 24, 2011	Apogenix provides update in the ongoing Phase II clinical trial of APG101 to treat Glioblastoma

2010

May 27, 2010	Data Published in “Nature” Confirms Development of APG101 to Treat Cancer
January 11, 2010	Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma

2009

November 16, 2009	Apogenix Receives Orphan Drug Designation for APG101 in the US and Positive Opinion on Orphan Product Designation in Europe
October 27, 2009	Apogenix Significantly Strengthens IP Protection for its Clinical Lead Compound APG101
July 29, 2009	Apogenix Receives Research Grants of EUR 2.6 Million as Partner of the Biotechnology Cluster Rhine-Neckar
May 13, 2009	Apogenix Reports Positive Phase I Results on its Lead Compound AGP101

2008

October 7, 2008	Apogenix Starts Phase I With its Lead Compound AGP101
September 19, 2008	Two Grants Totaling EUR 1.65 million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix ́ Research
April 30, 2008	Apogenix Raises EUR 27.5m in Series B Financing Round
March, 10, 2008	Publication in Cancer Cell Supports Therapeutic Potential of APG101 in Glioblastoma – New indication for lead compound of Apogenix

2007

October 10, 2007	New Publication Underlines Huge Potential of Apogenix ́ Compounds to Efficiently Eliminate Human Cancer Stem Cells
March 12, 2007	BMBF Grants 1.5m Euro to Further Evaluate the Therapeutic Potential of Apogenix' Lead Product APG101

2006

September 15, 2006

Apogenix receives positive opinion on orphan medicinal product designation from the European Medicines Agency for APG101, for prevention of Graft-versus-Host Disease